Qualitative differences between ranibizumab from original and ready to use syringes;Qualitätsunterschiede zwischen Ranibizumab aus Originalbehältern und aus Fertigspritzen

Ophthalmologe

Volumn 107, Issue 12, 2010, Pages 1123-1132

  Grisanti, S ^a   Tura, A ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Biological effectiveness; Light exposure; Ranibizumab; Storage period; Temperature

Indexed keywords

MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; QUALITY CONTROL; RETINA MACULA DEGENERATION; STANDARD; SYRINGE;

ANTIBODIES, MONOCLONAL; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN-ION CONCENTRATION; MACULAR DEGENERATION; QUALITY CONTROL; SYRINGES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650231717     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2299-0     Document Type: Article

References (8)

1. Boyer DS, Antoszyk AN et al; MARINA Study Group (2007) Subgroup analysis of the MARINA study of ranibizumab in neovasculqar age-related macular degeneration. Ophthalmology 114: 246-252.
2. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
3. Wolf A, Gandorfer A, Haritoglou C et al (2009) Volumenberechnungen zur aktuellen intravirealen Injektion von Lucentis. Ophthalmologe 107: 435-438.
4. Kahook MY, Liu L, Ruzycki P et al (2010) High-molecular weight aggregates in repackaged bevacizumab. Retina 30: 887-892.
5. Peters S, Julien S, Heiduschka P et al (2007) Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91: 827-831.
6. Bakri SJ, Snyder MR, Pulido JS et al (2006) Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26: 519-522.
7. Chen YH, Wu PC, Shiea J et al (2009) Evaluation of the sterility, stability and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther 25: 65-69.
8. Gerding H, Timmermann M (2010) Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study. Klin Monbl Augenheilkd 227: 269-272.